Endocrine Abstracts

Introduction: Correct titration of basal insulin is one of the most important conditions allowing Type 2 Diabetes Mellitus patients to reach correct and personalised fasting plasma glucose. The persistence of the pandemic, together with the persistence of the SARS-CoV2 virus made titration process more complex, and pushed the Lombardy diabetologists to develop solutions which could be handled by the patient independently, or with the remote online assistance of diabetes team.<...

Introduction: The long acting GLP-1 analogue, Semaglutide (S), is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM). Since November 2021, S has also been approved by the European Medicines Agency (EMA) at a dose of 2.4 mg for the treatment of obesity. Here, we report the efficacy of S, either alone or in combination with other antidiabetic drugs, in patients with T2DM and obesity on glycated hemoglobin (HBA1C) and weight loss.Pat...

Background: Obesity represents a threatening worldwide epidemic but, beyond the guidelines recommendations, its modalities of treatment in the medical community appear as variable and not clearly defined. Aim of our survey was to assess the present real-world approach to obesity management in Italy.Methods: Online anonymous survey among the 2248 members of the Italian Association of Clinical Endocrinologists (AME). The survey included 8 questions about d...

Tirzepatide, a once-weekly dual co-agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1) receptors, has been demonstrated to improve glucose control and reduced body weight in different therapeutic approaches. With this rapid review and meta-analysis, we systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin compared to basal insulin plus background treatments titrated rigorously t...